Brokerages expect that Advaxis, Inc. (NASDAQ:ADXS) will report sales of $2.40 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Advaxis’ earnings, with the highest sales estimate coming in at $3.00 million and the lowest estimate coming in at $1.79 million. Advaxis reported sales of $3.05 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 21.3%. The business is scheduled to issue its next quarterly earnings report on Monday, September 10th.
On average, analysts expect that Advaxis will report full year sales of $9.20 million for the current fiscal year, with estimates ranging from $7.39 million to $11.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $9.38 million per share, with estimates ranging from $7.16 million to $11.60 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Advaxis.
Advaxis (NASDAQ:ADXS) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. Advaxis had a negative net margin of 1,041.73% and a negative return on equity of 168.35%. The firm had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million.
A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Advaxis in a report on Tuesday, April 17th. Cantor Fitzgerald cut their price objective on shares of Advaxis from $19.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, March 13th. ValuEngine raised shares of Advaxis from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Jefferies Financial Group cut shares of Advaxis from a “buy” rating to a “hold” rating and cut their price objective for the company from $9.00 to $2.00 in a report on Wednesday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $3.33.
Advaxis traded up $0.01, reaching $1.69, on Monday, according to Marketbeat. The stock had a trading volume of 541,641 shares, compared to its average volume of 870,392. Advaxis has a 12-month low of $1.51 and a 12-month high of $7.45. The stock has a market capitalization of $97.35 million, a price-to-earnings ratio of -0.73 and a beta of 1.40.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADXS. Wells Fargo & Company MN increased its holdings in Advaxis by 39.9% in the fourth quarter. Wells Fargo & Company MN now owns 66,206 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 18,892 shares in the last quarter. DAFNA Capital Management LLC increased its holdings in Advaxis by 182.2% in the first quarter. DAFNA Capital Management LLC now owns 697,000 shares of the biotechnology company’s stock valued at $1,178,000 after buying an additional 450,000 shares in the last quarter. Bank of Montreal Can increased its holdings in Advaxis by 16,465.9% in the fourth quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock valued at $1,230,000 after buying an additional 430,583 shares in the last quarter. Deutsche Bank AG increased its holdings in Advaxis by 1,200.1% in the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock valued at $1,326,000 after buying an additional 431,379 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Advaxis during the fourth quarter worth about $1,398,000. 32.94% of the stock is owned by institutional investors.
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.